secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001193125-24-214186
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio reports positive trem-cel + Mylotarg data; plans pivotal trial
----------------------------------------------------------------------

- Phase 1/2 VBP101: 18 patients received trem-cel; 10 received Mylotarg as of July 19, 2024 cut-off.
- 100% engraftment (median 9 days); CD33 editing efficiency median 89%; full myeloid chimerism at Day 28.
- Shielding maintained neutrophil/platelet counts across Mylotarg doses 0.5, 1, 2 mg/m^2.
- Early relapse-free survival benefit vs high-risk AML comparators; only 4 relapses recorded.
- New preclinical ADC VADC45 targeting CD45; IND-enabling studies planned; FDA pivotal trial discussion by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312524214186/0001193125-24-214186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312524214186/d867599d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-214186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer